Sun Pharmaceutical Industries Ltd.

History

Year	Detail
1983	Sun Pharma established the first manufacturing facility for tablets and capsules at Vapi, Gujarat, India.
1988	launched Monotrate and Angize, our first cardiology products.
1991	Established our first research center to create a base for strong product and process development.
1995	Began production at API manufacturing plant in Panoli, Gujarat, India.
1996	Expanded sales network across 24 countries.
1997	Acquired Caraco Pharmaceutical Laboratories, U.S.
1999	Acquired Milmet Labs, Cephalexin, and 7ADCA actives manufacturing site in India.
2004	Commissioned the first joint venture manufacturing unit in Dhaka, Bangladesh.
2005	Acquired ICN’s business in Hungary.
2008	Acquired Chattem Chemicals Inc.
2014	Sun Pharma and Merck & Co. Inc. entered into a licensing agreement for Tildrakizumab.
2015	Acquired GSK’s Opiates business in Australia.
2016	Launched our first branded ophthalmic product, BromSite, in the U.S.
2019	Acquired Pola Pharma in Japan.
2022	Acquired Uractiv portfolio from Fiterman Pharma in Romania.
2023	Acquired Concert Pharmaceuticals.